CNS Pharmaceuticals announces 1-for-50 reverse stock split to meet Nasdaq's share price requirement.
Biopharmaceutical company CNS Pharmaceuticals announced a 1-for-50 reverse stock split to boost its share price and meet Nasdaq's minimum share price requirement. Effective June 4, every 50 shares of common stock will be consolidated into one, with warrants, equity-based awards, and other equity rights adjusted accordingly. Fractional shares will be rounded up, and the par value remains at $0.001 per share.
June 03, 2024
5 Articles